These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Thomas D; Giugliano RP Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833 [TBL] [Abstract][Full Text] [Related]
71. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Guimarães PO; Tricoci P Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244 [TBL] [Abstract][Full Text] [Related]
72. Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Koyabu Y; Abe S; Sakuma M; Kanaya T; Obi S; Yoneda S; Toyoda S; Nakajima T; Inoue T Intern Med; 2019 Aug; 58(16):2315-2322. PubMed ID: 31118376 [TBL] [Abstract][Full Text] [Related]
73. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy. Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668 [TBL] [Abstract][Full Text] [Related]
74. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction--a meta-regression of randomized controlled trials. Sethi A; Bajaj A; Bahekar A; Bhuriya R; Singh M; Ahmed A; Khosla S Catheter Cardiovasc Interv; 2013 Aug; 82(2):171-81. PubMed ID: 22961908 [TBL] [Abstract][Full Text] [Related]
75. Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity. Yoshida R; Takagi K; Ishii H; Morishima I; Tanaka A; Morita Y; Kanzaki Y; Nagai H; Watanabe N; Furui K; Shibata N; Yoshioka N; Yamauchi R; Komeyama S; Sugiyama H; Tsuboi H; Murohara T J Nucl Cardiol; 2021 Aug; 28(4):1422-1434. PubMed ID: 31428979 [TBL] [Abstract][Full Text] [Related]
76. Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial. Hochholzer W; Amann M; Titov A; Younas I; Löffelhardt N; Riede F; Potocnik C; Stratz C; Hauschke D; Trenk D; Neumann FJ; Valina CM JACC Cardiovasc Interv; 2016 Feb; 9(3):219-227. PubMed ID: 26777322 [TBL] [Abstract][Full Text] [Related]
77. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255 [TBL] [Abstract][Full Text] [Related]
78. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis. Bundhun PK; Huang F BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092 [TBL] [Abstract][Full Text] [Related]
80. Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. Liu Y; Liu H; Hao Y; Hao Z; Geng G; Han W; Chen Q; Wang D; Liu L; Jia K; Zhou Y Kardiol Pol; 2017; 75(9):850-858. PubMed ID: 28612911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]